Selinexor maintenance generated an improvement in progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer who responded to first-line chemotherapy.
CHICAGO — Pembrolizumab plus axitinib continued to confer a survival benefit vs. sunitinib at 5-year follow-up as first-line therapy for patients with advanced clear cell renal cell carcinoma, according to study results. The long-term data, presented at ASCO Annual Meeting, showed improved outcomes with the combination even though more patients in the sunitinib group had subsequent
/PRNewswire/ This week, the National Organization for Rare Disorders (NORD®) hosted the Living Rare, Living Stronger NORD Patient and Family Forum, NORD s.